AAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody development
Biotech company AAX Biotech today announced a partnership with evitria AG to enable the use of its Opti-mAb® technology in early antibody development workflows. STOCKHOLM, SWEDEN, April 23, 2026 /EINPresswire.com/ -- AAX Biotech develops proprietary …